Preservative-free versus preserved latanoprost eye drops for reducing intraocular pressure: a non-inferiority phase III randomized, multi-center, single-blind, parallel-group controlled trial by Theodosiadis, Panos et al.
Med Hypothesis Discov Innov Ophthalmol. 2020; 9(4)  
             Medical Hypothesis, Discovery &Innovation 




Preservative-free versus preserved latanoprost eye drops for 
reducing intraocular pressure: a non-inferiority phase III 
randomized, multi-center, single-blind, parallel-group 
controlled trial 
Panos Theodosiadis 1, Anastasios Konstas 2, Ioannis Halkiadakis 3, Vasiliki Dimera 4, Dimitrios Koufakis 5, Constantinos D 
Georgakopoulos 6, Evgenia Kanonidou 7, Elias Zintzaras 8, Konstantina Soulele 9, Antonios Margaritis 9, Lida Kalantzi 9  
1 Attikon University Hospital, Athens, Greece 
2 General University Hospital of Thessaloniki AHEPA, Thessaloniki, Greece 
3 Ophthalmiatreio Athens, Athens, Greece 
4 General Hospital of Larissa, Larissa, Thessaly, Greece 
5 IASO Thessalias, Larissa, Greece 
6 General University Hospital of Patra, Patra, Greece 
7 General Hospital of Thessaloniki Ippokrateio, Thessaloniki, Greece 
8 BECRO, Athens, Greece 
9 Pharmathen S.A., Attica, Greece 
ABSTRACT 
Background: The aim of this study was to test the non-inferiority of preservative-free (PF) latanoprost 50 μg/mL multi-dose ophthalmic solution versus the 
marketed benzalkonium chloride (BAK)-preserved latanoprost 50 μg/mL ophthalmic solution in patients with open-angle glaucoma and patients with ocular 
hypertension. 
Methods: This was a prospective, national, randomized, multi-center, observer-blind, parallel-group controlled clinical trial. Patients were randomized to receive 
either PF or BAK-preserved latanoprost once daily for 12 weeks. The primary endpoint was the change in intraocular pressure (IOP) at 8:00 AM in the affected 
eye between the end of the treatment (week 12) and the baseline (week 0). Secondary measurements were taken at weeks 2 and 6, with IOP being recorded 
at 8:00 AM, 12:00 PM, and 4:00 PM. 
Results: A total of 158 patients were included in the per protocol (PP) population (77 in the PF latanoprost treatment arm and 81 patients in the BAK-preserved 
latanoprost treatment arm). PF latanoprost was non-inferior to BAK-preserved latanoprost in reducing IOP at 8:00 AM in the study eye from the baseline (week 
0) to the end of the treatment (week 12). The point estimate of the between-treatment difference was 0.1 mmHg (95% confidence interval: -0.646, 0.847). 
Mean between-group differences in IOP reduction from the baseline to each of the secondary measurements were also similar between the two treatment 
arms. The two treatments were well tolerated and had comparable adverse event profiles. 
Conclusions: PF latanoprost was non-inferior to BAK-preserved latanoprost in reducing IOP in patients with open-angle glaucoma or ocular hypertension. Both 
treatments were well tolerated. 
KEY WORDS   
glaucoma, intraocular pressure, benzalkonium chloride, latanoprost, preservative-free, eye drop, randomized controlled trial, preservative-free 
 
Copyright © 2020, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 
International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, 
provided the original work is properly cited. 
Correspondence to: Dr. Lida Kalantzi PhD, Head of Scientific Affairs, Pharmathen S.A., 44, Kifissias Ave., 15125 Marousi Attica, Greece,        
E-mail: lkalantzi@pharmathen.com 
How to cite this article: Theodosiadis P, Konstas A.G, Halkiadakis I, Dimera V, Koufakis D, Georgakopoulos CD, Kanonidou E, Zintzaras E, 
Soulele K, Margaritis A, Kalantzi L, Preservative-free versus preserved latanoprost eye drops for reducing intraocular pressure: a non-inferiority 
phase III randomized, multi-center, single-blind, parallel-group controlled trial. Med Hypothesis Discov Innov Ophthalmol. 2020 Winter; 9(4): 




Med Hypothesis Discov Innov Ophthalmol. 2020; 9(4)  
274 PRESERVATIVE-FREE VERSUS A PRESERVED LATANOPROST EYE DROP FOR REDUCING IOP 
 
INTRODUCTION 
Latanoprost is a prostaglandin analog that is widely used 
in the treatment of high intraocular pressure (IOP) in 
patients with open-angle glaucoma and patients with 
ocular hypertension [1]. Latanoprost is actually a prodrug: 
upon instillation onto the cornea, latanoprost is rapidly 
hydrolyzed by topical esterases in the cornea to provide 
the pharmacologically active latanoprost acid [2]. 
One way latanoprost might reduce IOP is an increase in 
aqueous humor outflow. This pharmacodynamic effect is 
mediated by two main mechanisms. The first includes the 
enhancement of the pressure-sensitive trabecular outflow 
pathway, while the second is mediated through an 
increase in pressure-insensitive uveoscleral outflow [3, 4]. 
Following a single dose of latanoprost 0.005% ophthalmic 
solution, IOP reduction is maximal at 8–12 hours post-
instillation, with IOP remaining below the pretreatment 
levels for at least 24 hours. Thus, latanoprost 
administered once daily in the evening exerts a sustained 
IOP reduction, with the hypotensive effect being the 
greatest during the day [2, 5].  
Compared with other prostaglandin analogs, ophthalmic 
solutions of latanoprost exhibit higher ocular tolerability 
with fewer adverse events (AEs), indicating a more 
favorable efficacy and safety profile [6]. Since latanoprost 
eye drops usually contain a preservative, the impact of 
latanoprost on the AE profile of the formulation remains 
controversial [7]. In fact, preservative agents are generally 
considered to contribute to decreased ocular surface 
tolerability. Especially in patients receiving chronic 
treatments or suffering from underlying ocular surface 
diseases, topical AEs of preserved antiglaucoma 
medications should be carefully considered, as they may 
significantly influence patients’ compliance and quality of 
life [6]. 
Latanoprost is marketed as a 0.005% ophthalmic solution 
containing 0.02% preservative benzalkonium chloride 
(BAK) [6]. Efficacy and safety results from previous studies 
have suggested a similar efficacy and similar or better 
local tolerance of preservative-free (PF) latanoprost 
ophthalmic solutions compared with the marketed BAK-
preserved formulation, with less conjunctival hyperemia 
and less subjective symptoms upon instillation (such as 
burning, stinging, and pruritus) [6, 8-10]. 
Based on these data, the industry responded positively to 
addressing the needs of patients with sensitivity or allergy 
to BAK, with a number of single-dose PF antiglaucoma 
formulations approved during the last years [11, 12]. 
However, the use of single-dose packages can have a 
higher cost and may also be proven problematic in a 
subset of patients, such as in the elderly with decreased 
manual dexterity, which increases the potential for 
microbial contamination [13, 14].    
To accommodate this unmet patient need, a new, multi-
dose, PF latanoprost 50 μg/mL eye drops solution 
(Pharmathen S.A., Athens, Greece) has been developed, 
which is user-friendly and, at the same time, capable of 
maintaining a high product quality. The product is 
packaged in a novel multi-dose container with the Aero 
Pump 3K technology, which offers a three-part 
contamination protection: a specially designed filter that 
protects the product from microbiological contamination 
by using the enclosed air necessary for volume 
equalization, a silver spiral on the upper fraction to hinder 
bacterial growth, and a special valve system that stops 
backflow. 
Therefore, the aim of this study was to assess the non-
inferiority of this new PF formulation versus the BAK-
preserved product (Xalatan) in reducing IOP in patients 
with open-angle glaucoma and patients with ocular 
hypertension over a 12-week treatment period.  
METHODS 
Study design and participants 
This was a national, randomized, multi-center, observer-
blind, parallel-group controlled phase III clinical trial 
comparing PF latanoprost 50 μg/mL multi-dose 
ophthalmic solution (Pharmathen S.A., Athens, Greece) 
with BAK-preserved latanoprost 50 μg/mL (Xalatan; Pfizer 
Limited, Kent, UK). Due to differences in the medication 
packaging (PF latanoprost has a special container closure 
system that uses Aero Pump 3K technology), the 
investigator measuring the IOP was masked to the study 
medication. The study was conducted at seven clinical 
sites in Greece (General University Hospital of Athens 
Attikon, General University Hospital of Thessaloniki 
AHEPA, General Hospital of Larissa, Ophthalmiatreio 
Athens, IASO Thessalias, General University Hospital of 
Patra, and General Hospital of Thessaloniki Ippokrateio) 
between October 10, 2017 and February 23, 2018. The 
study protocol was prospectively approved by the 
National (Hellenic) Ethics Committee (NEC) (September 
15, 2017) and the National (Hellenic) Organization for 
Medicines (EOF) (September 26, 2017). The current study 
was conducted in compliance with the Declaration of 
Helsinki (2004) and Good Clinical Practice (GCP) 
guidelines. Relevant written informed consent was 
obtained from the patients prior to study enrollment. The 
study was registered in the EU Clinical Trials Register 
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database with trial identification number 2017-002910-
29. Eligible subjects were male or female patients (≥18 
years old) with unilateral or bilateral open-angle glaucoma 
or ocular hypertension. Following at least 4 weeks of 
washout of IOP-lowering medications, at baseline, 
patients were required to have an average IOP ≥ 22 mmHg 
and ≤ 35 mmHg in at least one eye and a best-corrected 
visual acuity ≥ 20/100 (Snellen) corresponding to the 
logarithm of minimal angle of resolution (logMAR) of 0.7. 
Patients were eligible for inclusion in the study if IOP was 
expected by the investigator to remain controlled with the 
new treatment without optic nerve damage or 
progression of visual field loss; arterial blood pressure was 
controllable; and no new systemic medication that may 
have altered the IOP (e.g., beta-blockers, calcium channel 
blockers, angiotensin-converting enzyme [ACE] inhibitors, 
and prostaglandins) had been taken in the previous 30 
days. The primary exclusion criteria were a history of 
chronic and recurrent inflammatory ocular disease, ocular 
trauma, or infections; a history of anterior chamber lens, 
torn posterior lens capsule, or corneal abnormalities that 
would preclude accurate IOP reading with an applanation 
tonometer; clinically significant or progressive retinal 
disease; narrow-angle/angle-closure glaucoma; 
intraocular surgery within the previous 3 months; aphakia 
or any known risk factor for cystoid macular edema; ocular 
laser surgery within the previous 1 month; cup/disk ratio 
> 0.8; best-corrected visual acuity ≤ 20/100 (Snellen), 
corresponding to worse than 0.7 logMAR score; treatment 
with topical, ocular, nonsteroidal anti-inflammatory 
drugs, local or systemic corticosteroids, or oral carbonic 
anhydrase inhibitors, or any change in systemic 
medication that affects IOP within the previous 30 days; 
and a history of allergic hypersensitivity or poor tolerance 
to any study medication component. Patients who were 
pregnant, breast-feeding, or of childbearing potential and 
not protected by a highly effective contraceptive method 
of birth control were also excluded from the study. The 
sample size of the participating population was calculated 
to obtain the required power for the demonstration of 
non-inferiority of PF latanoprost eye drops (test, T) 
compared to BAK-preserved latanoprost (control, C) in 
reducing IOP from baseline. For this calculation, the one-
sided significance level was set to 2.5%, and the power 
was set to 80%. A non-inferiority margin of 1.5 mmHg was 
used, as this tolerance criterion is usually employed and 
accepted in non-inferiority glaucoma studies [14-16], 
assuming a common standard deviation of the between-
group difference of 2.6, and a mean difference between 
the treatment groups of 0.3. With the above assumptions, 
a total sample size of 150 patients was initially required to 
be enrolled in the study, equally distributed to the 
respective treatment groups. Furthermore, since the 
primary analysis is typically based on the per protocol (PP) 
population, a dropout rate of approximately 15% was 
further assumed, leading to a total of 170 patients (i.e., 85 
patients per treatment group) being included in the study. 
Treatment and efficacy assessments  
Eligible patients were randomized at day 0 to receive 
once-daily treatment with either PF latanoprost 50 μg/mL 
or BAK-preserved latanoprost 50 μg/mL for a total 
duration of 12 weeks. Patients were instructed to instill 
one drop in each eye at approximately in the evening and 
were scheduled for follow-up visits at weeks 2, 6, and 12. 
As the clinical trial was observer-blind, due to differences 
in the medication packaging, to ensure masking, 
treatment allocation was carried out by personnel other 
than the observer. Patients were asked at each visit about 
their compliance with the treatment regimen, and their 
answers were recorded. To further assess compliance, 
patients were asked to return full and empty bottles of the 
eye drops at the end of the clinical trial and to keep a 
personal diary where the date and time of each instillation 
was recorded. Patients should bring the diary back at 
every scheduled visit (weeks 2, 6, and 12). 
IOP was measured using a calibrated Goldmann tonometer 
at 8:00 AM, 12:00 PM, and 4:00 PM (±1 h) at baseline and at 
weeks 2 (±2 days), 6 (±2 days), and 12 (±4 days). Two 
consecutive measurements were taken in each eye; if these 
two measurements differed by more than 4 mmHg, a third 
measurement was performed. The IOP for a given eye was 
calculated as the mean of two or three IOP measurements. 
Diurnal IOP was defined as the mean IOP at all time points 
during a visit. In patients with bilateral disease, where one of 
the two eyes satisfied the eligibility criteria (study eye), the 
contralateral eye was treated with BAK-preserved 
latanoprost 50 μg/mL, and the study eye was randomly 
assigned to one of the two study groups. If the criteria for 
evaluation were fulfilled for both eyes, the eye with the 
higher IOP at baseline was included.  
Safety assessments 
Safety evaluations included both ocular and systemic AEs, 
including a decrease in visual acuity as compared to baseline, 
changes in ocular signs based on slit-lamp biomicroscopy 
examination, subjective ocular findings (irritation, stinging, 
burning, eye dryness, and foreign body sensation), and vital 
signs (heart rate and blood pressure). The safety population 
(SP) consisted of all patients receiving at least one eye drop 
of PF or BAK-preserved latanoprost. Descriptive statistics 
were used to summarize the safety data (mean and standard 
deviation). Safety data were also compared, when 
appropriate, using the chi-square test or Fisher’s exact test, 
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based on the nature of the obtained data. Statistical 
significance was set at P < 0.05. All analyses were performed 
using IBM SPSS Statistics for Windows, version 24 (IBM Corp., 
Armonk, NY, USA). 
Efficacy endpoints and statistical analyses 
The intent-to-treat (ITT) population included all randomized 
patients who had at least one post-baseline IOP 
measurement. The PP population included all randomized 
patients who had no major protocol violations, completed 
IOP measurements, completed at least 12 weeks of 
treatment, and did not take prohibited medication. A 
primary efficacy analysis was performed in the PP 
population. For collateral purposes, an efficacy assessment 
was conducted on the ITT population. Missing data were not 
imputed. The primary efficacy endpoint to prove non-
inferiority was the change in IOP at 8:00 AM in the study eye 
from baseline to the end of the treatment (week 12). 
Comparison of treatments was performed using an analysis 
of covariance model (ANCOVA), with treatment as the main 
effect and baseline IOP as a covariate. The test medication 
was considered to be non-inferior to the control medication 
if the upper 95% confidence interval (CI) limit for the 
difference (T - C) was < ΔΝΙ, where ΔΝΙ = 1.5 mmHg was the 
defined non-inferiority criterion. This non-inferiority criterion 
is commonly used and accepted in non-inferiority glaucoma 
studies [14-16]. The center-by-treatment interaction was 
included as a fixed effect in the ANCOVA model for the 
primary endpoint. If the interaction was not significant, it was 
omitted from the analysis. Secondary efficacy endpoints 
included changes in IOP from baseline to each follow-up time 
point (week 12: 12:00 PM and 4:00 PM; weeks 2 and 6: 8:00 
AM, 12:00 PM, and 4:00 PM). Secondary efficacy analysis was 
performed using ANCOVA, with treatment as the main effect 
and baseline IOP as a covariate. The treatment difference and 
two-sided 95% CI for the difference were also obtained for 
the secondary endpoints.  
Ancillary statistical analyses in the PP population included 
ANCOVA to further assess the change in diurnal IOP from 
baseline to week 12 (with treatment as the main effect and 
baseline diurnal IOP as covariate). Additionally, a repeated 
measures general linear model was applied to investigate the 
trend of IOP over time, with treatment as a between-subjects 
factor and IOP at baseline, week 2, week 6, and week 12, or 
diurnal IOP as within-subjects variables. Analyses were 
performed for IOP measurements at 8:00 AM, 12:00 PM, and 
4:00 PM and for the mean diurnal IOP.  
RESULTS  
Patient distribution and baseline characteristics 
A total of 170 patients were randomized into the PF 
latanoprost group (86 patients) or the BAK-preserved 
latanoprost group (84 patients) (Figure 1). Of these, 158 
patients (77 patients in the PF latanoprost group and 81 
patients in the BAK-preserved latanoprost group) were 
finally included in the PP population. Twelve patients (7.1%; 
9 patients in the PF latanoprost group and 3 patients in the 
BAK-preserved latanoprost group) dropped out of the 
clinical trial, and the reasons are detailed in Figure 1.   
The baseline characteristics of the patients are listed in 
Table 1. The demographic and clinical characteristics 
were comparable between the two treatment groups at 
baseline. The treatment groups showed no statistically 
significant differences (P > 0.05) in terms of 
demographic and baseline clinical characteristics. All 
enrolled patients had well-controlled IOP before 
inclusion in the study. The difference in IOP between 
the test and control groups at all three baseline 
measurements at 8:00 AM, 12:00 PM, and 4:00 PM was 
not significant (P > 0.05 for all measurements). 
Treatment compliance was fairly good: 98.8%, 100%, 
and 100% for the test medication and 100%, 100%, and 
100% for the control medication at weeks 2, 6, and 12, 
respectively. 
Efficacy analysis 
The evaluation of non-inferiority of PF latanoprost versus 
BAK-preserved latanoprost was based on the PP population, 
as already mentioned. Both treatment groups showed a 
statistically significant mean decrease from baseline in the 
study eye IOP at all measured time points. The recorded 
mean changes in IOP from baseline until the end of the study 
ranged from -6.51 mmHg to -8.23 mmHg for the PF 
latanoprost group and from -6.8 mmHg to -8.16 mmHg for 
the BAK-preserved latanoprost group (Figure 2). Treatment 
compliance was similar between the two treatment groups. 
 PF latanoprost was non-inferior to BAK-preserved 
latanoprost for the primary efficacy endpoint, that is, the 
change in IOP at 8:00 AM in the study eye from baseline 
(week 0) to the end of the treatment (week 12). The point 
estimate of the between-treatment difference was 0.10 
mmHg (95% CI: -0.65, 0.85) in the PP population, with the 
upper limit of the 95% CI not exceeding the non-inferiority 
margin of 1.5 mmHg (Table 2, Figure 3).  
The center-by-treatment interaction was not significant (P 
= 0.781); therefore, it was omitted from the ANCOVA 
model. Non-inferiority of the two treatments was further 
confirmed in the ITT population, with the between-
treatment difference being 0.08 mmHg (95% CI: -0.681, 
0.836) and the upper limit of the 95% CI not exceeding the 
non-inferiority margin of 1.5 mmHg. Statistically non-
significant differences between the two treatment arms in 
changes in IOP from baseline at all-time points of each visit 
were further obtained during evaluation of the secondary 
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efficacy endpoints, which supported the primary efficacy 
analysis (Table 2). The mean diurnal IOP reductions from 
baseline to week 12 were also similar between the two 
treatment arms (Table 2). Ancillary analyses in the PP 
population performed for IOP measurements at 8:00 AM, 
12:00 PM, 4:00 PM and, also, for the diurnal IOP, by means 
of repeated measures in ANOVA, revealed a statistically 
significant effect of time (baseline and weeks 2, 6, and 12) 
(P < 0.001), while the treatment effect and the interaction 
between treatment and time were not significant (P > 
0.05), indicating that the variability of the treatment effect 





Figure 1. Patient allocation into the PF latanoprost (Pharmathen S.A.) or BAK-preserved latanoprost (Xalatan). Abbreviations: N, number; PF, preservative-
free; BAK, benzalkonium chloride; ITT, intent to treat; SP, safety population; PI, principal investigator; AE, adverse event; IOP, intraocular pressure; mmHg, 
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Table 1. Patient demographics and baseline characteristics of the PP population.  
 PF latanoprost 
(N = 77) 
BAK-preserved latanoprost 
(N = 81) 
P-value 
Age, years Mean (SD) 70.1 (9.5) 69.3 (9.2) 0.615 
Sex, Woman, n (%)  47 (61.0) 53 (65.4) 0.567 
Caucasian, n (%) 77 (100.0) 81 (100.0) 0.999 
Open-angle glaucoma, n (%) 55 (71.4) 51 (63.0) 0.258 
Bilateral disease (%) 64 (83.1) 65 (80.2) 0.641 
Comorbidities, n (%) 62 (80.5) 68 (84.0) 0.572 
History of allergies, n (%) 6 (7.8) 4 (4.9) 0.461 
Concomitant medications, n (%) 59 (76.6) 67 (82.7) 0.341 
History of ocular surgery, n (%) 25 (32.5) 29 (35.8) 0.659 
History of ocular laser surgery, n (%) 4 (5.2) 2 (2.5) 0.370 
IOP (mmHg) at 8:00 AM [mean (SD)] 24.6 (2.3) 24.2 (1.8) 0.281 
IOP (mmHg) at 12:00 PM [mean (SD)] 24.4 (2.0) 24.1 (1.9) 0.424 
IOP (mmHg) at 4:00 PM [mean (SD)] 24.0 (2.0) 23.7 (1.9) 0.266 
Diurnal mean IOP (mmHg) [mean (SD)] 24.3 (1.9) 24.0 (1.7) 0.281 
PP, per protocol; BAK, benzalkonium chloride; n, number; %, percentage; IOP, intraocular pressure; mmHg, millimeter of mercury; PF, preservative-free; 




Figure 2. Mean IOP (mmHg) at each assessment time for the per protocol population. Abbreviations: PF, preservative-free; BAK, benzalkonium chloride; 
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Figure 3. Forest plot showing the mean between-group difference in the change from baseline IOP. The least square mean and 95% confidence interval 
are presented. C, control; IOP, intraocular pressure; mmHg, millimeter of mercury; LL, lower limit; T, test; UL, upper limit. The medication used in the test 




Table 2. IOP change and 95% CIs for the difference in IOP from baseline to the pre-specified time points for PF and BAK-preserved latanoprost in the PP 
population. 
Time Mean ± SD IOP (mmHg)  
Primary efficacy endpoint  
                          Baseline                                                                    Week 12 
PF BAK PF BAK Difference a 95% CI b P-value 
8:00 AM 24.59 ± 2.30 24.24 ± 1.77 16.65 ± 2.66 16.36 ± 2.55 0.10 (-0.65, 0.85) 0.791 
Secondary efficacy endpoints  
                         Baseline                                                                    Week 2 
PF BAK PF BAK Difference 95% CI P-value 
8:00 AM 24.59 ± 2.30 24.24 ± 1.77 18.08 ± 2.64 17.43 ± 2.79 0.43 (-0.33, 1.19) 0.267 
12:00 PM 24.37 ± 2.00 24.12 ± 1.90 17.54 ± 2.50 7.01 ± 2.78 0.39 (-0.36, 1.17) 0.313 
4:00 PM 24.00 ± 1.98 23.65 ± 1.92 17.30 ± 2.41 16.76 ± 2.63 0.39 (-0.36, 1.14) 0.309 
Diurnal 24.32 ± 1.94 24.00 ± 1.72 17.64 ± 2.42 17.07 ± 2.66 - -  
                          Baseline                                                                    Week 6 
PF BAK PF BAK Difference 95% CI P-value 
8:00 AM 24.59 ± 2.30 24.24 ± 1.77 17.24 ± 2.42 16.89 ± 2.42 0.17 (-0.52, 0.86) 0.626 
12:00 PM 24.37 ± 2.00 24.12 ± 1.90 16.88 ± 2.33 16.43 ± 2.48 0.35 (-0.37, 1.07) 0.338 
4:00 PM 24.00 ± 1.98 23.65 ± 1.92 16.47 ± 2.35 16.33 ± 2.48 0.01 (-0.72, 0.74) 0.982 
Diurnal 24.32 ± 1.94 24.00 ± 1.72 16.86 ± 2.27 16.55 ± 2.37 - -  
                         Baseline                                                                    Week 12 
PF BAK PF BAK Difference 95% CI P-value 
12:00 PM 24.37 ± 2.00 24.12 ± 1.90 16.13 ± 2.42 15.95 ± 2.49 0.10 (-0.65, 0.84) 0.800 
4:00 PM 24.00 ± 1.98 23.65 ± 1.92 15.91 ± 2.37 15.83 ± 2.49 -0.02 (-0.77, 0.74) 0.967 
Diurnal 24.32 ± 1.94 24.00 ± 1.72 16.23 ± 2.41 16.05 ± 2.43 0.05 (-0.67, 0.78) 0.330 
aPF minus BAK; bfor all primary and secondary endpoints, the results were non-significant (P > 0.05). Abbreviations: PP, per protocol; CI, confidence 
interval; PF, preservative-free; BAK, benzalkonium chloride; IOP, intraocular pressure; mmHg, millimeter of mercury; %, percentage; SD, standard 
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Table 3. Summary of adverse events for the safety population. 
 PF latanoprost 
(N = 86) 
BAK-preserved latanoprost  
(N = 84) 
Deaths, n (%) 0 (0) 0 (0) 
Serious AEs, n (%) 0 (0) 0 (0) 
Discontinuation due to AEs, n (%) 1 (1.2) 0 (0) 
Patients with ≥1 AE, n (%) 22 (25.6) 31 (36.9) 
Total number of AEs, n (%) 39 (45.3) 45 (53.6) 
OCULAR AEs, n (%) 39 (48.1) 42 (51.9) 
               Mild ocular AEs, n (%) 31 (79.5) 28 (66.7) 
Blepharitis, n (%) 0 (0) 1 (2.4) 
Eye redness, n (%) 1 (2.6) 2 (4.8) 
Eye dryness, n (%) 3 (7.7) 3 (7.1) 
Punctate keratitis, n (%) 0 (0) 1 (2.4) 
Instillation site burning, n (%)  8 (20.5) 8 (19.1) 
Itching, n (%) 0 (0) 2 (4.8) 
Blurred vision, n (%) 3 (7.7) 3 (7.1) 
Eye stinging, n (%) 4 (10.3) 2 (4.8) 
Foreign body sensation, n (%) 4 (10.3) 4 (9.5) 
Eye irritation, n (%) 2 (5.1) 2 (4.8) 
Patient uncooperative, n (%) 2 (5.1) 0 (0) 
               Moderate ocular AEs, n (%) 8 (20.5) 14 (33.3) 
Increased IOP, n (%) 8 (20.5) 8 (19.1) 
No IOP control (≥22 mmHg), n (%) 0 (0) 1 (2.4) 
Conjunctival hyperemia, n (%) 4 (10.3) 5 (11.9) 
              Severe ocular AEs, n (%) 0 (0) 0 (0) 
SYSTEMIC AEs, n (%) 0 (0) 3 (3.6) 
             Mild systemic AEs, n (%) 0 (0) 2 (66.7) 
Headache, n (%) 0 (0) 1 (33.3) 
Skin erythema, n (%)  0 (0) 1 (33.3) 
            Moderate systemic AEs, n (%) 0 (0) 1 (33.3) 
Periocular skin irritation, n (%) 0 (0) 1 (33.3) 
            Severe systemic AEs, n (%) 0 (0) 0 (0) 
Abbreviations: N, number; %, percentage; AE, adverse event; BAK, benzalkonium chloride; IOP, intraocular pressure; PF, preservative-free.
 
Safety and tolerability 
PF latanoprost and BAK-preserved latanoprost 
demonstrated comparable safety profiles. No serious 
treatment-related AEs (including deaths) were reported. 
One premature discontinuation due to ocular AEs was 
reported (IOP increased ≥22 mmHg) in the PF latanoprost 
treatment arm. The SP consisted of 86 patients in the PF 
latanoprost arm and 84 patients in the BAK-preserved 
latanoprost arm. In total, 39 AEs were reported in 22 
patients in the PF latanoprost group (25.6%) and 45 AEs in 
31 patients in the BAK-preserved latanoprost group 
(36.9%). The vast majority of AEs were ocular and had 
similar intensity and frequency between the two groups 
(Table 3). The most common ocular AEs were instillation 
site burning and increased IOP (≥22 mmHg), followed by 
conjunctival hyperemia, foreign body sensation, blurred 
vision, eye stinging, eye dryness, eye irritation, eye 
redness, and blepharitis. No significant observations were 
noted in slit-lamp biomicroscopy findings in visual acuity 
change from baseline and vital signs in any of the two 
treatment arms. Of the three systemic AEs reported in the 
BAK-preserved latanoprost treatment arm, two were mild 
and one was of moderate intensity.  
DISCUSSION  
This phase III, randomized, single-blind controlled study 
demonstrated the non-inferiority of a novel multi-dose PF 
latanoprost eye drop formulation compared to the BAK-
preserved formulation in terms of reduction in IOP during 
a 12-week treatment period.  
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Both treatment groups showed a similar statistically 
significant mean decrease from baseline, in the study eye 
IOP, to the first assessment time-point (i.e., 2 weeks after 
treatment initiation), which was maintained for the entire 
duration of the study. Mean change in IOP from baseline 
up to 12 weeks ranged from -6.51 to -8.23 mmHg for the 
PF latanoprost group and from -6.8 to -8.16 for the BAK-
preserved latanoprost group. The point estimate for the 
primary efficacy endpoint was 0.10 mmHg in the PP 
population, with the upper limit of the range of the 
optimal reduction in IOP not exceeding the non-inferiority 
margin of 1.5 mmHg. PF latanoprost and BAK-preserved 
latanoprost formulations also presented a comparable 
safety profile, with no serious treatment-related AEs being 
reported.  
A clear trend has been observed over the last decade in 
the development and clinical use of PF ophthalmic 
solutions. Numerous clinical studies have demonstrated 
that switching from preserved to PF eye drops may 
alleviate ocular surface symptoms while maintaining 
efficacy at the same level [7, 8]. In the same vein, the 
substitution of preserved by PF topical antiglaucoma 
medications has been associated with an important 
increase in tear break-up time and amelioration of corneal 
staining and ocular surface disease index [6]. Therefore, 
published studies in the literature support the fact that PF 
prostaglandin ophthalmic solutions may present 
improved safety profiles concerning ocular-surface 
adverse events when compared to BAK-preserved 
solutions. BAK, the preservative used in latanoprost 
ophthalmic solution and the most commonly used ocular 
preservative, has been implicated in cases of ocular side 
effects, including conjunctival hyperemia. Previous 
studies have demonstrated that a high number of patients 
with glaucoma treated with topical eye drugs may have 
other underlying ocular surface diseases. In particular, as 
many as half of these patients appear to suffer from dry 
eye symptoms [17]. Furthermore, it has been suggested 
that extended exposure to BAK-preserved eye drops 
before filtering surgery may in some cases negatively 
affect surgical outcomes [18]. Based on these data, the 
emergence of a new generation of PF antiglaucoma 
medications is important, and BAK-free ophthalmic 
solutions should be available and used whenever 
required. Especially in patients suffering from pre-existing 
ocular surface diseases, or those with exposure to 
prolonged and concomitant preserved eye drop 
treatments, a condition that is often encountered in 
glaucoma patients, PF treatments could lead to better 
therapeutic adherence and potentially improve patients’ 
quality of life [8]. 
The current study was designed to assess the non-
inferiority of the test PF product in terms of efficacy 
parameters, namely reduction in IOP, compared to the 
control BAK-preserved product. The two products had a 
similar safety profile, with a slightly improved topical 
ocular tolerance of the PF formulation (i.e., fewer ocular 
AEs with lower severity and no systemic AEs). However, 
due to the current study setting, no conclusive evidence 
can be drawn in terms of safety, apart from the actual 
reporting of AEs recorded during the study. 
Until recently, only preserved eye drop solutions of 
latanoprost have been available. The presence of BAK was 
deemed mandatory for preventing bacterial 
contamination of the solution; however, new techniques 
and devices are now available that warrant the safe 
deployment of PF eye drop solutions [19]. Indeed, PF 
latanoprost formulations are now available, and clinical 
data show that these ophthalmic solutions can alleviate 
potential ocular surface symptoms and improve patient 
compliance [20, 21]. As demonstrated by different phase 
II and phase III studies with the first PF latanoprost single-
dose unit formulation (Monoprost; Laboratoires Théa, 
Clermont Ferrand, France), the efficacy of PF latanoprost 
was somewhat better than that of preserved latanoprost 
[6, 20]. 
Similarly, the present study demonstrated the non-
inferiority of a new multi-dose PF latanoprost ophthalmic 
solution compared to the traditional multi-dose BAK-
preserved latanoprost, in terms of IOP reduction. The 
percentage of IOP reduction observed from baseline to 
week 12 (32.3% for PF latanoprost and 32.51% for BAK-
preserved latanoprost) was within the range of optimal 
IOP reduction (between -22% and -39%), which was also 
observed with other marketed PF latanoprost ophthalmic 
solutions [6, 8, 20, 21]. Similar reductions in IOP were 
observed for the two formulations throughout the 
duration of the study, with comparable efficacy at all 
intermediate time points, and a similar AE profile.  
A potential limitation of the current study was the 
selection of a single morning IOP assessment as the 
primary endpoint for the comparison of the two 
formulations. However, this methodology is supported by 
several clinical arguments, including: i) the fact that in 
most patients with glaucoma, peak IOP generally occurs in 
the morning; ii) the plethora of previously published non-
inferiority studies following the same methodology; and 
iii) preclinical and clinical studies indicating that the 
morning time point is the most challenging time to 
demonstrate non-inferiority in IOP between two 
formulations [9, 22]. Thus, it can be suggested that the 
IOP-lowering effect of PF latanoprost compared to the 
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BAK-preserved formulation can be extrapolated from the 
single morning IOP efficacy endpoint.  
Another potential limitation was the single-blinded nature 
of the study, as lack of treatment masking could 
potentially influence patients’ feelings regarding their 
treatment. A double-masked design might have been 
more appropriate, but this was not feasible because of the 
differences in the packaging systems between the two 
drugs; the investigational medicinal product is a PF 
preparation, which has a special container closure system. 
It should be noted, however, that the applied study 
procedures warranted that single masking was preserved 
and controlled by the study personnel, other than the 
principal investigator, and also by instructing study 
participants not to disclose information relevant to study 
treatment to the investigator.  
Finally, a third limitation that can be considered was the 
rather short 12-week treatment period of the current 
study, which may not allow for an adequate investigation 
of the long-term side effects of the two latanoprost 
formulations. However, the current study setting was 
designed to allow for the assessment of the non-inferiority 
of the test PF product in terms of efficacy parameters (i.e., 
reduction in IOP) and to record the AE profiles of the two 
drugs. In this respect, the 12-week study period is a well-
established treatment duration for topically applied 
prostaglandin analogs [6, 21].   
Overall, the findings of the present study further 
confirmed that the IOP-lowering efficacy of latanoprost is 
not dependent on the presence of BAK, confirming 
previously reported results [6]. In fact, it has been 
suggested that BAK, through its detergent activity, may 
improve the effectiveness of topically applied drugs by 
enhancing their penetration into the eye and delivery into 
the cornea [17]. Indeed, PF prostaglandin-containing eye 
drops have shown decreased epithelial permeability and 
better maintenance of membrane integrity [22-24]. 
However, numerous clinical studies and meta-analyses 
have confirmed this claim by demonstrating equal IOP-
lowering efficacy between PF and BAK-preserved 
prostaglandin analogs [6, 9, 17]. 
 
CONCLUSIONS 
Taken together, the current study demonstrated the non-
inferiority of PF latanoprost eye drops compared to BAK-
preserved latanoprost eye drops in terms of IOP 
reduction, along with a good tolerability profile. The PF 
latanoprost 50 μg/mL formulation is a new multi-dose 
ophthalmic solution that may provide an efficacious 
alternative for glaucoma/ocular hypertension patients 
with existing ocular surface disease who do not tolerate 
eye drops with preservatives, especially when long-term 
treatment is required.  
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